Paolini John F. 4

What Happened
John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals (KNSA), had 2,497 restricted share units (RSUs) convert into Class A ordinary shares on April 7, 2026. To satisfy tax withholding, 1,208 of those shares were retained/withheld at $48.94 per share for a total withholding value of $59,120, leaving a net issuance of 1,289 shares to Paolini. The Form 4 records the RSU conversion (transaction code M) and the tax withholding (transaction code F).

Key Details

• Transaction date: 2026-04-07; Form 4 filed 2026-04-08 (timely).
• RSUs converted: 2,497 shares.
• Shares withheld for taxes: 1,208 at $48.94 each; withholding value $59,120.
• Net shares issued to insider: 2,497 − 1,208 = 1,289 shares.
• Footnotes: F1 clarifies each RSU equals one Class A Ordinary Share; F2 notes RSUs vest 25% each year on the April 7 anniversary of the 2022 grant.
• Shares owned after the transaction: not disclosed in the filing.

Context

• This was a routine vesting of RSUs with shares withheld to cover tax liability (a common, non-market-sale event). The Form shows a conversion of derivative awards into shares and the accompanying tax withholding rather than an open-market sale or purchase.
• Transaction codes: M = conversion/exercise of derivative (the RSU conversion); F = payment of exercise price or tax liability (share withholding).
• No indication of a 10b5-1 plan or other special arrangement was reported; the filing appears timely.